elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q36250418-20588FB3-2A75-4877-8B3B-B34314E3A294
Q36250418-20588FB3-2A75-4877-8B3B-B34314E3A294
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36250418-20588FB3-2A75-4877-8B3B-B34314E3A294
A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.
P2860
Q36250418-20588FB3-2A75-4877-8B3B-B34314E3A294
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36250418-20588FB3-2A75-4877-8B3B-B34314E3A294
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
11b0dbb4ad7030cd4361d01032b97f02602a84cd
P2860
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.